ArticleCancer science2024

Aberrant TIMP-1 production in tumor-associated fibroblasts drives the selective benefits of nintedanib in lung adenocarcinoma.

Paula Duch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.